<DOC>
	<DOCNO>NCT01697592</DOCNO>
	<brief_summary>This study examine safety efficacy addition omarigliptin Japanese participant type 2 diabetes mellitus inadequate glycemic control diet/exercise therapy oral antihyperglycemic agent monotherapy .</brief_summary>
	<brief_title>Omarigliptin ( MK-3102 ) Clinical Trial - Add-on Oral Antihyperglycemic Agent Study Japanese Participants With Type 2 Diabetes Mellitus ( MK-3102-015 )</brief_title>
	<detailed_description>The treatment period compose 24-week double-blind period ( Phase A ) 28-week open-label period ( Phase B ) . During Phase A , participants receive either omarigliptin 25 mg match placebo . During Phase , B participant receive omarigliptin 25 mg. All participant remain stable dose administration single oral antihyperglycemic basal medication .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Has type 2 diabetes mellitus Has inadequate glycemic control diet/exercise therapy oral antihyperglycemic agent monotherapy History type 1 diabetes mellitus history ketoacidosis History follow medication : Thiazolidinediones ( TZD ) ( participant whose basal medication TZD ) and/or insulin within 12 week prior study participation , omarigliptin anytime</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>